Summary

Hormone Replacement Therapy market is projected to attain a value of US$ 35.86 Billion by 2032. In 2023, the worldwide hormone replacement therapy market was appraised to be worth US$ 20.91 Billion, and it increased at a compound annual growth rate of 6.18% from 2024 to 2032.


Global Hormone Replacement Therapy Analysis

Hormone replacement therapy (HRT) uses medications that contain female hormones to replenish the estrogen that the body no longer produces after menopause. HRT can help alleviate menopause symptoms such as hot flashes and night sweats. It can also minimize bone loss and fractures in postmenopausal women. HRT subtypes are based on naturally occurring hormones like progesterone, estrogen, and testosterone. Menopause is a frequently reported consequence of age-related hormonal changes occurring around the age of 50.

The World Population Prospects 2022 report reveals that the global population is expected to increase significantly soon. The United Nations predicts that by 2030, the world's population could reach 8.5 Billion, The world population by 2050 and 2100. Women's bodies are susceptible to hormonal changes, which can cause a various of issues such as weight gain, memory decline, fatigue, low libido, aging appearance, and muscle loss.

The NHSBSA Statistics and Data Science department reported that in 2022-23, 11 million hormone replacement therapy (HRT) items were prescribed in England, an increase of 47% from the previous year. Approximately 2.3 million patients received HRT prescriptions, a 29% increase from the prior year. The report also highlighted that patients in the least deprived areas were prescribed HRT items more than twice as frequently as those in the most deprived areas. Finally, the proportion of HRT prescriptions exempt from prescription charges increased from April 2023, a reversal of the downward trend observed since 2015-16.


Global Hormone Replacement Therapy Trends

Rising R&D and product approvals are expected to aid the growth of the hormonal therapy market. Ascendis Pharma A/S's drug SKYTROFA received market authorization in January 2022 for treating growth hormone disorders in children and adolescents. In November 2021, I-MAB Biopharma Co., Ltd. partnered with Jumpcan Pharmaceutical Group to market and develop eftansomatropin alfa, named TJ101, in China to treat pediatric growth hormone insufficiency.

The rising prevalence of menopausal symptoms and increased awareness of post-menopausal challenges are key drivers advancing the global HRT market. China's economic development and policies have increased women's awareness of self-care and participation in physical examinations. Studies have shown that menopausal symptoms are prevalent in women, with rates as high as 73.8% in community groups and perimenopausal women in rural India being more prone to symptoms compared to pre-menopausal and post-menopausal women.

The prevalence of hormonal imbalances and related disorders is increasing, leading to a rise in demand for hormone replacement therapy. This therapy involves administering synthetic or natural hormones to replace deficient levels of hormones in the body. It is particularly beneficial for individuals experiencing symptoms like hot flashes, mood swings, and reduced libido. The growing awareness of its benefits and the availability of advanced hormone replacement therapies are expected to drive market growth.


United States Hormone Replacement Therapy Market

The US has the biggest market for Hormone Replacement Therapy, with rising utilization among patients over 35 years old. The availability of intensified drugs and an increase in the target population drive market growth. The rise in the release of generic hormone replacement therapy medicines and advances in drug delivery technologies are also contributing factors. NIH reports almost half of post-menopausal US women have used HRT. 1.3 Million American women enter menopause each year. Conjugated equine estrogens/bazedoxifene tablets are available for menopausal VMS treatment and osteoporosis prevention. The American Thyroid Association has predicted that over 12% of the US population will experience a thyroid disorder during their lifetime, affecting almost 20 million Americans every year. This high incidence of thyroid hormone imbalance is expected to boost the studied market in the region. Additionally, in June 2022, Astellas Pharma Inc. submitted a New Drug Application for fezolinetant, seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.


Hormone Replacement Therapy Market Company News

Some of the prominent player in the Hormone Replacement Therapy Market are Abbott Laboratories, Bayer AG, Eli Lilly & Company, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Abbvie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd, and Dr. Reddy’s Laboratories Ltd.


• In February 2023, Korea’s Ministry of Food and Drug Safety approved Pfizer’s NGENLA for treating growth hormone deficiency.
• Pfizer Inc. finished obtaining Arena Pharmaceuticals in 2022. This acquisition will prompt an upgrade in the portfolio to dermatology, cardiology, gastroenterology, and so forth.
• In February 2022, MHLW of Japan approved NGENLA of Pfizer, Inc., and OPKO, a long-lasting pediatric growth hormone deficiency treatment. This strategic initiative helps companies expand their customer base in different geographies and boost their revenue.
• In June 2022, Halozyme Therapeutics launched TLANDO, an oral treatment to replace endogenous testosterone in adult males with a deficiency or absence.
• In August 2022, Akorn received FDA approval to launch its Generic-Cetrorelix Acetate Injection (0.25 mg). Cetrorelix blocks premature ovulation during ovarian stimulation, making eggs more suitable for fertilization.


Product Type – Global Hormone Replacement Therapy Market breakup in 5 viewpoints:

1. Estrogen Hormone Replacement Therapy
2. Human Growth Hormone Replacement Therapy
3. Thyroid Hormone Replacement Therapy
4. Testosterone Hormone Replacement Therapy
5. Progestogen Hormone Replacement Therapy


Disease Type – Global Hormone Replacement Therapy Market breakup in 5 viewpoints:

1. Menopause
2. Hypothyroidism
3. Male Hypogonadism
4. Growth Hormone Deficiency
5. Others


Route of Administration – Global Hormone Replacement Therapy Market breakup in 3 viewpoints:

1. Oral
2. Parental
3. Others


Distribution Channels – Global Hormone Replacement Therapy Market breakup in 3 viewpoints:

1. Hospitals Pharmacies
2. Retail Pharmacies & Stores
3. Online Pharmacies


Country – Global Hormone Replacement Therapy Market breakup of 25 Countries Covered in the Report:

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis


Company Analysis:

1. Abbott Laboratories
2. Bayer AG
3. Eli Lilly & Company
4. Novartis AG
5. Novo Nordisk A/S
6. Pfizer Inc.
7. Abbvie Inc. (Allergan plc)
8. Teva Pharmaceutical Industries Ltd
9. Dr. Reddy’s Laboratories Ltd

ページTOPに戻る

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges


5. Global Hormone Replacement Therapy Market

6. Market Share – Global Hormone Replacement Therapy Market

6.1 By Therapy Type
6.2 By Disease Type
6.3 By Route of Administration
6.4 By Distribution Channel
6.5 By Country


7. Therapy Type – Global Hormone Replacement Therapy Market

7.1 Estrogen Hormone Replacement Therapy
7.2 Human Growth Hormone Replacement Therapy
7.3 Thyroid Hormone Replacement Therapy
7.4 Testosterone Hormone Replacement Therapy
7.5 Progestogen Hormone Replacement Therapy


8. Disease Type - Global Hormone Replacement Therapy Market

8.1 Menopause
8.2 Hypothyroidism
8.3 Male Hypogonadism
8.4 Growth Hormone Deficiency
8.5 Others


9. Route of Administration – Global Hormone Replacement Therapy Market

9.1 Oral
9.2 Parental
9.3 Others


10. Distribution Channel – Global Hormone Replacement Therapy Market

10.1 Hospitals Pharmacies
10.2 Retail Pharmacies & Stores
10.3 Online Pharmacies


11. Country – Global Hormone Replacement Therapy Market

11.1 North America

11.1.1 United States
11.1.2 Canada

11.2 Europe

11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherlands
11.2.8 Turkey

11.3 Asia Pacific

11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Thailand
11.3.6 Malaysia
11.3.7 Indonesia
11.3.8 Australia
11.3.9 New Zealand

11.4 Latin America

11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina

11.5 Middle East & Africa

11.5.1 Saudi Arabia
11.5.2 UAE
11.5.3 South Africa


12. Porter’s Five Analysis – Global Hormone Replacement Therapy Market

12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes


13. SWOT Analysis – Global Hormone Replacement Therapy Market

13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat


14. Company Analysis

14.1 Abbott Laboratories

14.1.1 Company Overview
14.1.2 Product Portfolio
14.1.3 Recent Development
14.1.4 Financial Performance

14.2 Bayer AG

14.2.1 Company Overview
14.2.2 Product Portfolio
14.2.3 Recent Development
14.2.4 Financial Performance

14.3 Eli Lilly & Company

14.3.1 Company Overview
14.3.2 Product Portfolio
14.3.3 Recent Development
14.3.4 Financial Performance

14.4 Novartis AG

14.4.1 Company Overview
14.4.2 Product Portfolio
14.4.3 Recent Development
14.4.4 Financial Performance

14.5 Novo Nordisk A/S

14.5.1 Company Overview
14.5.2 Product Portfolio
14.5.3 Recent Development
14.5.4 Financial Performance

14.6 Pfizer Inc.

14.6.1 Company Overview
14.6.2 Product Portfolio
14.6.3 Recent Development
14.6.4 Financial Performance

14.7 Abbvie Inc. (Allergan plc)

14.7.1 Company Overview
14.7.2 Product Portfolio
14.7.3 Recent Development
14.7.4 Financial Performance

14.8 Teva Pharmaceutical Industries Ltd

14.8.1 Company Overview
14.8.2 Product Portfolio
14.8.3 Recent Development
14.8.4 Financial Performance

14.9 Dr. Reddy’s Laboratories Ltd

14.9.1 Company Overview
14.9.2 Product Portfolio
14.9.3 Recent Development
14.9.4 Financial Performance

ページTOPに戻る

List of Tables/Graphs

Table-01: Global – Hormone Replacement Therapy Market Share by Therapy Type (Percent), 2019 – 2023
Table-02: Global – Forecast for Hormone Replacement Therapy Market Share by Therapy Type (Percent), 2024 – 2032
Table-03: Global – Hormone Replacement Therapy Market Share by Disease Type (Percent), 2019 – 2023
Table-04: Global – Forecast for Hormone Replacement Therapy Market Share by Disease Type (Percent), 2024 – 2032
Table-05: Global – Hormone Replacement Therapy Market Share by Route of Administration (Percent), 2019 – 2023
Table-06: Global – Forecast for Hormone Replacement Therapy Market Share by Route of Administration (Percent), 2024 – 2032
Table-07: Global – Hormone Replacement Therapy Market Share by Distribution Channel (Percent), 2019 – 2023
Table-08: Global – Forecast for Hormone Replacement Therapy Market Share by Distribution Channel (Percent), 2024 – 2032
Table-09: Global – Hormone Replacement Therapy Market Share by Countries (Percent), 2019 – 2023
Table-10: Global – Forecast for Hormone Replacement Therapy Market Share by Countries (Percent), 2024 – 2032